Pharma BD Deal Intelligence

Janssen Biotech, Inc. (Johnson & Johnson) / MacroGenics, Inc.

2016 · Co-Development · $740M · Complete

Announcement Sentiment

Strongly positive

MacroGenics granted Janssen a global, exclusive license to MGD015, a preclinical CD3 x tumor-target bispecific DART molecule. MacroGenics received $75M upfront plus up to $665M in clinical, regulatory, and commercialization milestones (~$740M total) plus tiered royalties on global sales. Second deal between the parties (followed 2014 MGD011 deal).

Key facts

Announced May 31, 2016
Closed Jun 28, 2016
Deal value $740M
Deal type Co-Development
Therapeutic area Hematologic malignancies and solid tumors
Indications Hematologic malignancies and solid tumors
Key assets MGD015
Mechanism CD3 x undisclosed tumor target bispecific DART (Dual-Affinity Re-Targeting) antibody

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals